Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 12/2018

Open Access 01-12-2018 | Original Research Article

A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life

Authors: Jan-Frederik Schlender, Donato Teutonico, Katrin Coboeken, Katrin Schnizler, Thomas Eissing, Stefan Willmann, Ulrich Jaehde, Heino Stass

Published in: Clinical Pharmacokinetics | Issue 12/2018

Login to get access

Abstract

Background

Physiologically-based pharmacokinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug pharmacokinetics by continuous knowledge integration.

Objective

The objective of this study was to build a ciprofloxacin PBPK model for intravenous and oral dosing based on a comprehensive literature review, and evaluate the predictive performance towards pediatric and geriatric patients.

Methods

The aim of this report was to establish confidence in simulations of the ciprofloxacin PBPK model along the development process to facilitate reliable predictions outside of the tested adult age range towards the extremes of ages. Therefore, mean data of 69 published clinical trials were identified and integrated into the model building, simulation and verification process. The predictive performance on both ends of the age scale was assessed using individual data of 258 subjects observed in own clinical trials.

Results

Ciprofloxacin model verification demonstrated no concentration-related bias and accurate simulations for the adult age range, with only 4.8% of the mean observed data points for intravenous administration and 12.1% for oral administration being outside the simulated twofold range. Predictions towards the extremes of ages for the area under the plasma concentration–time curve (AUC) and the maximum plasma concentration (Cmax) over the entire span of life revealed a reliable estimation, with only two pediatric AUC observations outside the 90% prediction interval.

Conclusion

Overall, this ciprofloxacin PBPK modeling approach demonstrated the predictive power of a thoroughly informed middle-out approach towards age groups of interest to potentially support the decision-making process.
Appendix
Available only for authorised users
Literature
1.
Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885–8.PubMed
2.
Hoffler D, Dalhoff A, Gau W, Beermann D, Michl A. Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol. 1984;3:363–6.PubMed
3.
Olivera ME, Manzo RH, Junginger HE, Midha KK, Shah VP, Stavchansky S, et al. Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride. J Pharm Sci. 2011;100:22–33.PubMed
4.
Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11–23.PubMed
5.
Honeybourne D, Wise R, Andrews JM. Ciprofloxacin penetration into lungs. Lancet. 1987;1:1040.PubMed
6.
Naber KG, Sorgel F, Kees F, Jaehde U, Schumacher H. Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration. Am J Med. 1989;87:57S–9S.PubMed
7.
Wolff M, Boutron L, Singlas E, Clair B, Decazes JM, Regnier B. Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis. Antimicrob Agents Chemother. 1987;31:899–902.PubMedPubMedCentral
8.
Rohwedder RW, Bergan T, Thorsteinsson SB, Scholl H. Transintestinal elimination of ciprofloxacin. Diagn Microbiol Infect Dis. 1990;13:127–33.PubMed
9.
Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther. 1995;58:532–41.PubMed
10.
Bergan T, Dalhoff A, Rohwedder R. Pharmacokinetics of ciprofloxacin. Infection. 1988;16(Suppl 1):S3–13.PubMed
11.
Sorgel F, Naber KG, Jaehde U, Reiter A, Seelmann R, Sigl G. Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. Am J Med. 1989;87:62S–5S.PubMed
12.
Payen S, Serreau R, Munck A, Aujard Y, Aigrain Y, Bressolle F, et al. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother. 2003;47:3170–8.PubMedPubMedCentral
13.
Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol. 2003;43:698–710.PubMed
14.
Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993;37:1065–72.PubMedPubMedCentral
15.
Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, et al. Applied concepts in PBPK modeling: how to Build a PBPK/PD Model. CPT Pharmacometrics Syst Pharmacol. 2016;5:516–31.PubMedPubMedCentral
16.
Yoshida K, Budha N, Jin JY. Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: frequent utilization in the field of oncology. Clin Pharmacol Ther. 2017;101:597–602.PubMedPubMedCentral
17.
van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008;23:422–30.PubMed
18.
Lipman J, Scribante J, Gous AG, Hon H, Tshukutsoane S. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother. 1998;42:2235–9.PubMedPubMedCentral
19.
Ruhnke M, Trautmann M, Borner K, Hopfenmuller W. Pharmacokinetics of ciprofloxacin in liver cirrhosis. Chemotherapy. 1990;36:385–91.PubMed
20.
Frost RW, Lettieri JT, Krol G, Shamblen EC, Lasseter KC. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Clin Pharmacol Ther. 1989;45:608–16.PubMed
21.
Hackam DJ, Christou N, Khaliq Y, Duffy DR, Vaughan D, Marshall JC, et al. Bioavailability of oral ciprofloxacin in early postsurgical patients. Arch Surg. 1998;133:1221–5.PubMed
22.
Cohn SM, Cohn KA, Rafferty MJ, Smith AH, Degutis LC, Kowalsky SF, et al. Enteric absorption of ciprofloxacin during the immediate postoperative period. J Antimicrob Chemother. 1995;36:717–21.PubMed
23.
Gattis WA, Petros WP, Pickard WW, Drew RH, May DB, Hathorn JW. A prospective, open-label study of single-dose ciprofloxacin absorption after chemotherapy in patients with malignancy. Pharmacotherapy. 1997;17:836–40.PubMed
24.
Johnson EJ, MacGowan AP, Potter MN, Stockley RJ, White LO, Slade RR, et al. Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. J Antimicrob Chemother. 1990;25:837–42.PubMed
25.
Shah A, Lettieri J, Nix D, Wilton J, Heller AH. Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob Agents Chemother. 1995;39:1003–6.PubMedPubMedCentral
26.
Bayer A, Gajewska A, Stephens M, Stark JM, Pathy J. Pharmacokinetics of ciprofloxacin in the elderly. Respiration. 1987;51:292–5.PubMed
27.
Israel D, Gillum JG, Turik M, Harvey K, Ford J, Dalton H, et al. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1993;37:2193–9.PubMedPubMedCentral
28.
Wacha H, Wagner D, Schafer V, Knothe H. Concentration of ciprofloxacin in bone tissue after single parenteral administration to patients older than 70 years. Infection. 1990;18:173–6.PubMed
29.
Gonzalez MA, Moranchel AH, Duran S, Pichardo A, Magana JL, Painter B, et al. Multiple-dose ciprofloxacin dose ranging and kinetics. Clin Pharmacol Ther. 1985;37:633–7.PubMed
30.
Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of intravenous ciprofloxacin at three different doses. J Antimicrob Chemother. 1988;22:715–20.PubMed
31.
Borner K, Hoffken G, Lode H, Koeppe P, Prinzing C, Glatzel P, et al. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol. 1986;5:179–86.PubMed
32.
Hoffken G, Lode H, Prinzing C, Borner K, Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother. 1985;27:375–9.PubMedPubMedCentral
33.
Dudley MN, Ericson J, Zinner SH. Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. Antimicrob Agents Chemother. 1987;31:1782–6.PubMedPubMedCentral
34.
Bergan T, Thorsteinsson SB, Kolstad IM, Johnsen S. Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. Eur J Clin Microbiol. 1986;5:187–92.PubMed
35.
Bergan T, Thorsteinsson SB, Solberg R, Bjornskau L, Kolstad IM, Johnsen S. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med. 1987;82:97–102.PubMed
36.
Wingender W, Graefe KH, Gau W, Forster D, Beermann D, Schacht P. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol. 1984;3:355–9.PubMed
37.
Wise R, Lockley RM, Webberly M, Dent J. Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother. 1984;26:208–10.PubMedPubMedCentral
38.
Drusano GL, Plaisance KI, Forrest A, Standiford HC. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother. 1986;30:440–3.PubMedPubMedCentral
39.
Gonzalez MA, Moranchel AH, Duran S, Pichardo A, Magana JL, Painter B, et al. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother. 1985;28:235–9.PubMedPubMedCentral
40.
Nix DE, Spivey JM, Norman A, Schentag JJ. Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses. Ann Pharmacother. 1992;26:8–10.PubMed
41.
Garraffo R, Drugeon HB. Comparative assessment of the pharmacokinetics and pharmacodynamics of ciprofloxacin after single i.v. doses of 200 and 400 mg. Drugs. 1995;49(Suppl 2):317–20.PubMed
42.
Plaisance KI, Drusano GL, Forrest A, Bustamante CI, Standiford HC. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1987;31:956–8.PubMedPubMedCentral
43.
Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1987;31:860–4.PubMedPubMedCentral
44.
Pea F, Milaneschi R, Baraldo M, Lugatti E, Talmassons G, Furlanut M. Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. Ther Drug Monit. 2000;22:386–91.PubMed
45.
Cios A, Wyska E, Szymura-Oleksiak J, Grodzicki T. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. Exp Gerontol. 2014;57:107–13.PubMed
46.
Kees F, Naber KG, Meyer GP, Grobecker H. Pharmacokinetics of ciprofloxacin in elderly patients. Arzneimittelforschung. 1989;39:523–7.PubMed
47.
Hirata CA, Guay DR, Awni WM, Stein DJ, Peterson PK. Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. Antimicrob Agents Chemother. 1989;33:1927–31.PubMedPubMedCentral
48.
Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother. 1987;31:915–9.PubMedPubMedCentral
49.
Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1986;30:444–6.PubMedPubMedCentral
50.
Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance. Eur J Clin Microbiol Infect Dis. 1989;8:515–20.PubMed
51.
Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992;36:993–6.PubMedPubMedCentral
52.
Catchpole C, Andrews JM, Woodcock J, Wise R. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother. 1994;33:103–10.PubMed
53.
Shah A, Lettieri J, Kaiser L, Echols R, Heller AH. Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily. J Antimicrob Chemother. 1994;33:795–801.PubMed
54.
Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet. 1998;352:522–7.PubMed
55.
Peltola H, Ukkonen P, Saxen H, Stass H. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children. Pediatrics. 1998;101:658–62.PubMed
56.
Peltola H, Vaarala M, Renkonen OV, Neuvonen PJ. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob Agents Chemother. 1992;36:1086–90.PubMedPubMedCentral
57.
Shah A, Liu MC, Vaughan D, Heller AH. Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. J Antimicrob Chemother. 1999;43 Suppl A:49–54.PubMed
58.
Davis RL, Koup JR, Williams-Warren J, Weber A, Smith AL. Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob Agents Chemother. 1985;28:74–7.PubMedPubMedCentral
59.
Ball K, Jamier T, Parmentier Y, Denizot C, Mallier A, Chenel M. Prediction of renal transporter-mediated drug–drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling. Eur J Pharm Sci. 2017;106:122–32.PubMed
60.
Gonzalez MA, Uribe F, Moisen SD, Fuster AP, Selen A, Welling PG, et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1984;26:741–4.PubMedPubMedCentral
61.
Ledergerber B, Bettex JD, Joos B, Flepp M, Luthy R. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother. 1985;27:350–2.PubMedPubMedCentral
62.
Aronoff GE, Kenner CH, Sloan RS, Pottratz ST. Multiple-dose ciprofloxacin kinetics in normal subjects. Clin Pharmacol Ther. 1984;36:384–8.PubMed
63.
Tartaglione TA, Raffalovich AC, Poynor WJ, Espinel-Ingroff A, Kerkering TM. Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. Antimicrob Agents Chemother. 1986;29:62–6.PubMedPubMedCentral
64.
LeBel M, Bergeron MG, Vallee F, Fiset C, Chasse G, Bigonesse P, et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother. 1986;30:260–6.PubMedPubMedCentral
65.
Brumfitt W, Franklin I, Grady D, Hamilton-Miller JM, Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984;26:757–61.PubMedPubMedCentral
66.
Loi CM, Parker BM, Cusack BJ, Vestal RE. Aging and drug interactions. III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther. 1997;280:627–37.PubMed
67.
Bergan T, Delin C, Johansen S, Kolstad IM, Nord CE, Thorsteinsson SB. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother. 1986;29:298–302.PubMedPubMedCentral
68.
Wagenlehner FM, Wydra S, Onda H, Kinzig-Schippers M, Sorgel F, Naber KG. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother. 2003;47:3789–94.PubMedPubMedCentral
69.
Kara M, Hasinoff BB, McKay DW, Campbell NR. Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol. 1991;31:257–61.PubMedPubMedCentral
70.
Crump B, Wise R, Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983;24:784–6.PubMedPubMedCentral
71.
Boy D, Well M, Kinzig-Schippers M, Sorgel F, Ankel-Fuchs D, Naber KG. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents. 2004;23(Suppl 1):S6–16.PubMed
72.
Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest. 2001;119:1114–22.PubMed
73.
Esposito S, Miniero M, Barba D, Sagnelli E. Pharmacokinetics of ciprofloxacin in impaired liver function. Int J Clin Pharmacol Res. 1989;9:37–41.PubMed
74.
Gasser TC, Ebert SC, Graversen PH, Madsen PO. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. Antimicrob Agents Chemother. 1987;31:709–12.PubMedPubMedCentral
75.
Boerema JB, Dalhoff A, Debruyne FM. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy. 1985;31:13–8.PubMed
76.
LeBel M, Barbeau G, Bergeron MG, Roy D, Vallee F. Pharmacokinetics of ciprofloxacin in elderly subjects. Pharmacotherapy. 1986;6:87–91.PubMed
77.
Frost RW, Carlson JD, Dietz AJ Jr, Heyd A, Lettieri JT. Ciprofloxacin pharmacokinetics after a standard or high-fat/high-calcium breakfast. J Clin Pharmacol. 1989;29:953–5.PubMed
78.
Overholser BR, Kays MB, Forrest A, Sowinski KM. Sex-related differences in the pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol. 2004;44:1012–22.PubMed
79.
Gallicano K, Sahai J. Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Br J Clin Pharmacol. 1996;42:632–4.PubMed
80.
Dan M, Verbin N, Gorea A, Nagar H, Berger SA. Concentrations of ciprofloxacin in human liver, gallbladder, and bile after oral administration. Eur J Clin Pharmacol. 1987;32:217–8.PubMed
81.
Dan M, Zuabi T, Quassem C, Rotmensch HH. Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams. Antimicrob Agents Chemother. 1992;36:677–8.PubMedPubMedCentral
82.
Weinstein MP, Deeter RG, Swanson KA, Gross JS. Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers. Antimicrob Agents Chemother. 1991;35:2352–8.PubMedPubMedCentral
83.
Yuk JH, Nightingale CN, Quintiliani R. Ciprofloxacin levels when receiving sucralfate. JAMA. 1989;262:901.PubMed
84.
Dan M, Golomb J, Gorea A, Braf Z, Berger SA. Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother. 1986;30:88–9.PubMedPubMedCentral
85.
Chandler MH, Toler SM, Rapp RP, Muder RR, Korvick JA. Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. Antimicrob Agents Chemother. 1990;34:442–7.PubMedPubMedCentral
86.
Guay DR, Awni WM, Peterson PK, Obaid S, Stein D, Breitenbucher R, et al. Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. Int J Clin Pharmacol Ther Toxicol. 1988;26:279–84.PubMed
87.
Lubart E, Berkovitch M, Leibovitz A, Britzi M, Soback S, Bukasov Y, et al. Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between nasogastric tube and oral administration. Ther Drug Monit. 2013;35:653–6.PubMed
88.
Aggarwal P, Dutta S, Garg SK, Narang A. Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. Indian Pediatr. 2004;41:1001–7.PubMed
89.
Alvarez AI, Perez M, Prieto JG, Molina AJ, Real R, Merino G. Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008;97:3483–93.PubMed
90.
Vanwert AL, Srimaroeng C, Sweet DH. Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol. 2008;74:122–31.PubMedPubMedCentral
91.
Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther. 2004;76:598–606.PubMed
92.
Parry MF, Smego DA, Digiovanni MA. Hepatobiliary kinetics and excretion of ciprofloxacin. Antimicrob Agents Chemother. 1988;32:982–5.PubMedPubMedCentral
93.
Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci. 2011;100:5324–45.PubMed
94.
Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006;45:683–704.PubMed
95.
Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45:1013–34.PubMed
96.
Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, et al. Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. Clin Pharmacokinet. 2016;55(12):1573–89.PubMedPubMedCentral
97.
Willmann S, Becker C, Burghaus R, Coboeken K, Edginton A, Lippert J, et al. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet. 2014;53:89–102.PubMed
98.
99.
Barbosa J, Barrón D, Jiménez-Lozano E, Sanz-Nebot V. Comparison between capillary electrophoresis, liquid chromatography, potentiometric and spectrophotometric techniques for evaluation of pK a values of zwitterionic drugs in acetonitrile–water mixtures. Anal Chim Acta. 2001;437:309–21.
100.
Varanda F, Pratas de Melo MJ, Caco AI, Dohrn R, Makrydaki FA, Voutsas E, et al. Solubility of antibiotics in different solvents. 1. Hydrochloride forms of tetracycline, moxifloxacin, and ciprofloxacin. Ind Eng Chem Res. 2006;45:6368–74.
101.
Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Fois F. W. S. PK-Sim: a physiologically based pharmacokinetic ‘whole-body’ model. Biosilico. 2003;1:121–4.
102.
Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol. 2005;1:159–68.PubMed
103.
Leibovitz E, Janco J, Piglansky L, Press J, Yagupsky P, Reinhart H, et al. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J. 2000;19:1060–7.PubMed
104.
Mehrotra N, Bhattaram A, Earp JC, Florian J, Krudys K, Lee JE, et al. Role of quantitative clinical pharmacology in pediatric approval and labeling. Drug Metab Dispos. 2016;44:924–33.PubMed
105.
106.
107.
Jadhav PR, Cook J, Sinha V, Zhao P, Rostami-Hodjegan A, Sahasrabudhe V, et al. A proposal for scientific framework enabling specific population drug dosing recommendations. J Clin Pharmacol. 2015;55:1073–8.PubMed
108.
Lau S, Schlender JF, Abernethy DR, Burckart GJ, Golden A, Slattum PW, et al. Improving therapeutics to better care for older adults and the young: report from the American College of Clinical Pharmacology Workshop. J Clin Pharmacol. 2018;58:277–80.
109.
Martinez M, Mistry B, Lukacova V, Polli J, Hoag S, Dowling T, et al. Use of modeling and simulation tools for understanding the impact of formulation on the absorption of a low solubility compound: ciprofloxacin. AAPS J. 2016;18:886–97.PubMed
110.
Staib AH, Beermann D, Harder S, Fuhr U, Liermann D. Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule). Am J Med. 1989;87:66S–9S.PubMed
111.
Maharaj AR, Edginton AN. Examining small intestinal transit time as a function of age: is there evidence to support age-dependent differences among children? Drug Metab Dispos. 2016;44:1080–9.PubMed
112.
Leroux S, Turner MA, Guellec CB, Hill H, van den Anker JN, Kearns GL, et al. Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design. Clin Pharmacokinet. 2015;54:1273–85.PubMed
113.
Zhao W, Hill H, Le Guellec C, Neal T, Mahoney S, Paulus S, et al. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. Antimicrob Agents Chemother. 2014;58:6572–80.PubMedPubMedCentral
114.
Sadiq MW, Nielsen EI, Khachman D, Conil JM, Georges B, Houin G, et al. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. J Pharmacokinet Pharmacodyn. 2017;44:69–79.PubMed
115.
Navid A, Ng DM, Wong SE, Lightstone FC. Application of a physiologically based pharmacokinetic model to study theophylline metabolism and its interactions with ciprofloxacin and caffeine. CPT Pharmacometrics Syst Pharmacol. 2016;5:74–81.PubMedPubMedCentral
116.
Hansmann S, Miyaji Y, Dressman J. An in silico approach to determine challenges in the bioavailability of ciprofloxacin, a poorly soluble weak base with borderline solubility and permeability characteristics. Eur J Pharm Biopharm. 2018;122:186–96.PubMed
Metadata
Title
A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
Authors
Jan-Frederik Schlender
Donato Teutonico
Katrin Coboeken
Katrin Schnizler
Thomas Eissing
Stefan Willmann
Ulrich Jaehde
Heino Stass
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 12/2018
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-018-0661-6

Other articles of this Issue 12/2018

Clinical Pharmacokinetics 12/2018 Go to the issue

Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Propofol

Original Research Article

Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug–Drug Interactions

Acknowledgement to Referees

Acknowledgement to Referees

Original Research Article

Identification of Cytochrome P450-Mediated Drug–Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model

Review article

Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole

Original Research Article

Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease